RxDoctor Payments Data

Grzegorz Kurzydlo

Neurology · Humble, TXNPI 1083611925

Payments from drug & device makers

$9,136in general payments, 2019–2025

Across 533 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$994
  • Teva Pharmaceuticals USA, Inc.$715
  • EMD Serono, Inc.$617
  • Novartis$616
  • SK Life Science, Inc.$555
  • Neurelis, Inc.$493
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$9,114100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)66$994
Teva Pharmaceuticals USA, Inc.72$715
EMD Serono, Inc.31$617
Novartis39$616
SK Life Science, Inc.25$555
Neurelis, Inc.16$493
Acadia Pharmaceuticals Inc20$386
Lundbeck LLC17$331
Argenx US, Inc.12$301
Biohaven Pharmaceuticals, Inc.20$253
Axsome Therapeutics, Inc.12$234
TG Therapeutics, Inc.9$232
Impel Pharmaceuticals Inc.18$229
Amneal Pharmaceuticals LLC12$196
Amgen(2 entities)11$186
Eisai Inc.10$183
Lilly USA, LLC10$183
Arbor Pharmaceuticals, Inc.11$174
Livanova USA, Inc.7$157
Otsuka America Pharmaceutical, Inc.9$153
Biogen8$139
Azurity Pharmaceuticals, Inc.8$137
Biohaven Pharmaceutical Holding Company Ltd.7$136
Avanir Pharmaceuticals, Inc.7$132
Neurocrine Biosciences, Inc.9$127
UCB, Inc.4$112
Supernus Pharmaceuticals, Inc.5$97
Mallinckrodt Hospital Products Inc.4$95
Impel Pharmaceuticals LLC5$89
Assertio Therapeutics, Inc.4$81
Catalyst Pharmaceuticals, Inc.3$77
Idorsia Pharmaceuticals US Inc5$70
Genentech USA, Inc.3$64
Pfizer4$63
Harmony Biosciences LLC2$56
Scilex Pharmaceuticals Inc.3$51
Promius Pharma LLC3$50
Aquestive Therapeutics, Inc.3$44
Ultragenyx Pharmaceutical Inc.2$39
Upsher-smith Laboratories LLC2$38
Bristol Myers Squibb2$33
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$31
Jazz Pharmaceuticals Inc.1$23
Kedrion Biopharma, Inc.1$23
Collegium Pharmaceutical, Inc.1$22
Otsuka Pharmaceutical Development & Commercialization, Inc.1$22
Sanofi-aventis U.S. LLC1$18
Almatica Pharma LLC1$16
Merck1$14
Avion Pharmaceuticals1$13
Kowa Pharmaceuticals America, Inc.1$13
Abbott1$13
Itamar Medical Inc1$10

How this compares

$9,136 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$131,289
Medicare patients
166
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5045$941,060
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$181,834
Nurtec OdtRimegepant Sulfate45$64,935
UbrelvyUbrogepant15$17,964
Aimovig AutoinjectorErenumab-Aooe14$16,143
ValtocoDiazepam12$14,333
QuliptaAtogepant13$13,050
Lurasidone Hcl26$7,398
Gabapentin388$6,656
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen214$6,616
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine114$3,904
Topiramate ErTopiramate24$3,358
Memantine Hcl140$2,962
Ropinirole Hcl112$2,702
Oxcarbazepine46$2,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$63$246,76957 claims
AbbVieUbrelvy, Qulipta$994$31,01428 claims
Neurelis, Inc.Valtoco$493$14,33312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →